PD-L1-话题@MedSci

#PD-L1#

309篇内容 | 7581人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1254981, encodeId=5c78125498187, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JTO：淋巴细胞浸润、PD-L1、吸烟史之间是何种微妙关系，它们如何影响未曾接受免疫抑制剂治疗的非小细胞肺癌患者的预后？, objectType=article, longId=159657, objectId=718f15965eed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=718f15965eed, replyNumber=0, likeNumber=76, createdTime=2019-02-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=718f15965eed, moduleTitle=JTO：淋巴细胞浸润、PD-L1、吸烟史之间是何种微妙关系，它们如何影响未曾接受免疫抑制剂治疗的非小细胞肺癌患者的预后？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=718f15965eed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254980, encodeId=78201254980a2, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-1/PD-L1肿瘤免疫治疗分子标志物大全, objectType=article, longId=156053, objectId=9faf15605366, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9faf15605366, replyNumber=0, likeNumber=73, createdTime=2018-12-19, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9faf15605366, moduleTitle=PD-1/PD-L1肿瘤免疫治疗分子标志物大全, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9faf15605366)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254979, encodeId=2bbd12549e90e, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=EMBO J：VGLL4缺失抑制PD-L1的表达并参与抗肿瘤免疫调控的作用机制, objectType=article, longId=155405, objectId=4c18155405ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c18155405ce, replyNumber=0, likeNumber=77, createdTime=2018-12-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c18155405ce, moduleTitle=EMBO J：VGLL4缺失抑制PD-L1的表达并参与抗肿瘤免疫调控的作用机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c18155405ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254978, encodeId=0b4b12549e878, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=穹兮寰宇叹无穷，参兮纷繁咏何粲-李媛教授细述PD-L1诊断, objectType=article, longId=154770, objectId=4330154e7000, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4330154e7000, replyNumber=0, likeNumber=87, createdTime=2018-12-02, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4330154e7000, moduleTitle=穹兮寰宇叹无穷，参兮纷繁咏何粲-李媛教授细述PD-L1诊断, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4330154e7000)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254977, encodeId=67a412549e787, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JCO：PD-1/PD-L1抑制剂初始治疗NSCLC 糖皮质激素让抗癌神药部分失效, objectType=article, longId=154370, objectId=61761543e050, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61761543e050, replyNumber=0, likeNumber=78, createdTime=2018-11-27, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61761543e050, moduleTitle=JCO：PD-1/PD-L1抑制剂初始治疗NSCLC 糖皮质激素让抗癌神药部分失效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61761543e050)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254976, encodeId=359412549e612, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=World J Urol：在尿路上皮癌中，PD-1/PD-L1抑制作用的响应预测因子研究, objectType=article, longId=153216, objectId=92ec15321684, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92ec15321684, replyNumber=0, likeNumber=74, createdTime=2018-11-12, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92ec15321684, moduleTitle=World J Urol：在尿路上皮癌中，PD-1/PD-L1抑制作用的响应预测因子研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92ec15321684)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254975, encodeId=ff0712549e5fb, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=BMJ：PD-L1表达阴性患者 PD-1/PD-1抑制剂也能大幅延长生存期, objectType=article, longId=153166, objectId=251515316657, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=251515316657, replyNumber=0, likeNumber=85, createdTime=2018-11-11, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=251515316657, moduleTitle=BMJ：PD-L1表达阴性患者 PD-1/PD-1抑制剂也能大幅延长生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=251515316657)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254974, encodeId=dc7112549e489, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=NEJM：无论PD-L1表达水平帕博利珠单抗一线治疗转移性NSCLC鳞癌生存获益显著, objectType=article, longId=152644, objectId=1a4c15264424, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a4c15264424, replyNumber=0, likeNumber=66, createdTime=2018-11-04, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a4c15264424, moduleTitle=NEJM：无论PD-L1表达水平帕博利珠单抗一线治疗转移性NSCLC鳞癌生存获益显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a4c15264424)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254973, encodeId=b83612549e3fc, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=一滴血就能预测PD-1/PD-L1免疫治疗效果，是真的吗？, objectType=article, longId=152270, objectId=cdcc1522e05b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdcc1522e05b, replyNumber=0, likeNumber=65, createdTime=2018-10-31, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdcc1522e05b, moduleTitle=一滴血就能预测PD-1/PD-L1免疫治疗效果，是真的吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdcc1522e05b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254972, encodeId=675612549e287, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=全球第6款PD-1/PD-L1肿瘤免疫疗法获批上市，竞争趋白热化！, objectType=article, longId=150497, objectId=844b15049ed6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=844b15049ed6, replyNumber=0, likeNumber=77, createdTime=2018-10-08, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=844b15049ed6, moduleTitle=全球第6款PD-1/PD-L1肿瘤免疫疗法获批上市，竞争趋白热化！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=844b15049ed6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254971, encodeId=4fd712549e188, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=CLIN CANCER RES：MET致癌活化和JAK2失活会影响肺癌PD-L1表达, objectType=article, longId=150102, objectId=1ff11501029e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ff11501029e, replyNumber=0, likeNumber=102, createdTime=2018-10-02, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ff11501029e, moduleTitle=CLIN CANCER RES：MET致癌活化和JAK2失活会影响肺癌PD-L1表达, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ff11501029e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254970, encodeId=171d12549e06d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=马军教授：PD-1/PD-L1抑制剂在淋巴瘤领域中前景无限, objectType=article, longId=149879, objectId=d9c41498e99b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9c41498e99b, replyNumber=0, likeNumber=81, createdTime=2018-09-30, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9c41498e99b, moduleTitle=马军教授：PD-1/PD-L1抑制剂在淋巴瘤领域中前景无限, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9c41498e99b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254969, encodeId=73be12549693c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌, objectType=article, longId=149623, objectId=297e149623e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=297e149623e6, replyNumber=0, likeNumber=75, createdTime=2018-09-27, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=297e149623e6, moduleTitle=阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=297e149623e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254968, encodeId=655b1254968f6, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Blood：在弥漫性大B细胞淋巴瘤中，B细胞受体介导的NFATc1激活可诱导IL-10/STAT3/PD-L1信号, objectType=article, longId=148786, objectId=bee6148e86b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bee6148e86b0, replyNumber=0, likeNumber=124, createdTime=2018-09-15, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bee6148e86b0, moduleTitle=Blood：在弥漫性大B细胞淋巴瘤中，B细胞受体介导的NFATc1激活可诱导IL-10/STAT3/PD-L1信号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bee6148e86b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254967, encodeId=bf8d125496e7e, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=BMJ：PD-L1在癌症中的表达状态与PD-1或PD-L1抑制剂的疗效, objectType=article, longId=148592, objectId=7d6414859221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d6414859221, replyNumber=0, likeNumber=72, createdTime=2018-09-12, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d6414859221, moduleTitle=BMJ：PD-L1在癌症中的表达状态与PD-1或PD-L1抑制剂的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d6414859221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254966, encodeId=28ae125496625, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=JCO：基线类固醇对非小细胞肺癌患者PD-1/PD-L1阻断治疗有效性的影响, objectType=article, longId=147190, objectId=3dc814e1907e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dc814e1907e, replyNumber=0, likeNumber=79, createdTime=2018-08-23, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dc814e1907e, moduleTitle=JCO：基线类固醇对非小细胞肺癌患者PD-1/PD-L1阻断治疗有效性的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dc814e1907e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254965, encodeId=3b001254965b4, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Mol Cell:华人科学家首次发现二甲双胍可降解PD-L1，解除癌细胞对免疫细胞的压制，提高抗癌能力, objectType=article, longId=146968, objectId=288314696892, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=288314696892, replyNumber=0, likeNumber=86, createdTime=2018-08-20, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=288314696892, moduleTitle=Mol Cell:华人科学家首次发现二甲双胍可降解PD-L1，解除癌细胞对免疫细胞的压制，提高抗癌能力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=288314696892)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254964, encodeId=7bad1254964f5, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=NATURE：外泌体PD-L1助力免疫抑制, objectType=article, longId=146378, objectId=1f661463e8fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f661463e8fa, replyNumber=0, likeNumber=75, createdTime=2018-08-12, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f661463e8fa, moduleTitle=NATURE：外泌体PD-L1助力免疫抑制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f661463e8fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254963, encodeId=3d0e12549638d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Chest：EBUS-TBNA与切除肺癌标本之间PD-L1免疫组化染色的比较, objectType=article, longId=145644, objectId=2f25145644a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f25145644a6, replyNumber=0, likeNumber=75, createdTime=2018-08-03, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f25145644a6, moduleTitle=Chest：EBUS-TBNA与切除肺癌标本之间PD-L1免疫组化染色的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f25145644a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1254962, encodeId=2cd01254962d3, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Blood：在自然杀伤T细胞淋巴瘤中，STAT3信号通路激活可上调PD-L1的表达！, objectType=article, longId=145638, objectId=7bf3145638e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bf3145638e4, replyNumber=0, likeNumber=89, createdTime=2018-08-03, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bf3145638e4, moduleTitle=Blood：在自然杀伤T细胞淋巴瘤中，STAT3信号通路激活可上调PD-L1的表达！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bf3145638e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1

2020-05-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JTO：淋巴细胞浸润、PD-L1、吸烟史之间是何种微妙关系，它们如何影响未曾接受免疫抑制剂治疗的非小细胞肺癌患者的预后？

2019-02-10

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-1/PD-L1肿瘤免疫治疗分子标志物大全

2018-12-19

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

EMBO J：VGLL4缺失抑制PD-L1的表达并参与抗肿瘤免疫调控的作用机制

2018-12-10

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

穹兮寰宇叹无穷，参兮纷繁咏何粲-李媛教授细述PD-L1诊断

2018-12-02

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JCO：PD-1/PD-L1抑制剂初始治疗NSCLC 糖皮质激素让抗癌神药部分失效

2018-11-27

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

World J Urol：在尿路上皮癌中，PD-1/PD-L1抑制作用的响应预测因子研究

2018-11-12

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

BMJ：PD-L1表达阴性患者 PD-1/PD-1抑制剂也能大幅延长生存期

2018-11-11

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

NEJM：无论PD-L1表达水平帕博利珠单抗一线治疗转移性NSCLC鳞癌生存获益显著

2018-11-04

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

一滴血就能预测PD-1/PD-L1免疫治疗效果，是真的吗？

2018-10-31

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

全球第6款PD-1/PD-L1肿瘤免疫疗法获批上市，竞争趋白热化！

2018-10-08

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

CLIN CANCER RES：MET致癌活化和JAK2失活会影响肺癌PD-L1表达

2018-10-02

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

马军教授：PD-1/PD-L1抑制剂在淋巴瘤领域中前景无限

2018-09-30

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌

2018-09-27

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Blood：在弥漫性大B细胞淋巴瘤中，B细胞受体介导的NFATc1激活可诱导IL-10/STAT3/PD-L1信号

2018-09-15

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

BMJ：PD-L1在癌症中的表达状态与PD-1或PD-L1抑制剂的疗效

2018-09-12

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

JCO：基线类固醇对非小细胞肺癌患者PD-1/PD-L1阻断治疗有效性的影响

2018-08-23

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Mol Cell:华人科学家首次发现二甲双胍可降解PD-L1，解除癌细胞对免疫细胞的压制，提高抗癌能力

2018-08-20

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

NATURE：外泌体PD-L1助力免疫抑制

2018-08-12

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Chest：EBUS-TBNA与切除肺癌标本之间PD-L1免疫组化染色的比较

2018-08-03

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Blood：在自然杀伤T细胞淋巴瘤中，STAT3信号通路激活可上调PD-L1的表达！

2018-08-03

科室
- - 订阅+
  - 更多科室
工具
服务